Sage Journals: Discover world-class research

Abstract

Background: Cardiopulmonary bypass (CPB) evokes a systemic inflammatory response. In attempting to improve the biocompatibility of the equipment, various methods to coat the inner surfaces of the CPB systems have been developed. The present study compares a Trillium Biopassive surface-coated Affinity oxygenator with a Duraflo II totally heparin-coated CPB system.

Methods: Low-risk patients admitted for primary coronary artery bypass grafting or aortic valve replacement were randomized to operation using the Trillium- or the Duraflo II-coated setups. Heparin concentration, complement activation (C3bc activation products and terminal complement complex (TCC)), platelet activation (platelet numbers and beta-thromboglobulin (BTG)), leukocyte activation (leukocyte numbers and myeloperoxidase (MPO)), coagulation (thrombin/antithrombin complexes (TAT)) and fibrinolytic activity (plasmin/a₂-antiplasmin complexes (PAP)) were measured during CPB and two hours postoperatively.

Results: Platelet counts decreased during CPB, without significant intergroup differences. The median BTG concentration increased moderately in both groups and were slightly higher in the Trillium group during CPB (p B-0.05), but not postoperatively. Complement activation products (C3bc and TCC), leukocyte counts, MPO, TAT and PAP activity showed no differences between the two groups.

Conclusions: There were small differences in the inflammatory response between the two extracorporeal circulation devices compared in this study.

Get full access to this article

View all access options for this article.

References

van Oeveren W , Kazatchkine MD , Descamps-Latscha B , et al. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation . J Thorac Cardiovasc Surg 1985; 89: 888-899 .

Kirklin JK , Westaby S , Blackstone EH , Kirklin JW , Chenoweth DE , Pacifico AD. Complement and the damaging effects of cardiopulmonary bypass . J Thorac Cardiovasc Surg 1983; 86: 845-857 .

Moore FD Jr , Warner KG , Assousa S , Valeri CR , Khuri SF. The effects of complement activation during cardiopulmonary bypass. Attenuation by hypothermia, heparin, and hemodilution . Ann Surg 1988; 208: 95-103 .

Moen O , Hogasen K , Fosse E , et al. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass . Ann Thorac Surg 1997; 63: 105-111 .

Nilsson L , Peterson C , Venge P , Borowiec JW , Thelin S. Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating . Ann Thorac Surg 1995; 59: 713-716 .

Fukutomi M , Kobayashi S , Niwaya K , Hamada Y , Kitamura S. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment . Artif Organs 1996; 20: 767-776 .

Videm V , Svennevig JL , Fosse E , Semb G , Osterud A , Mollnes TE. Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations . J Thorac Cardiovasc Surg 1992; 103: 806-813 .

Videm V , Mollnes TE , Fosse E , et al. Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population . J Thorac Cardiovasc Surg 1999; 117: 794-802 .

Fosse E , Thelin S , Svennevig JL , et al. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: a European multicentre study . Eur J Cardiothorac Surg 1997; 11: 320-327 .

10.

Mollnes TE , Videm V , Riesenfeld J , et al. Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials . Clin Exp Immunol 1991; 86: 21-26 .

11.

Videm V , Fosse E , Mollnes TE , Garred P , Svennevig JL. Complement activation with bubble and membrane oxygenators in aortocoronary bypass grafting . Ann Thorac Surg 1990; 50: 387-391 .

12.

Mollnes TE , Lea T , Harboe M. Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay . Scand J Immunol 1984; 20: 157-166 .

13.

Garred P , Mollnes TE , Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3 . Scand J Immunol 1988; 27: 329-335 .

14.

Mollnes TE , Lea T , Froland SS , Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex . Scand J Immunol 1985; 22: 197-202 .

15.

Videm V , Nilsson L , Venge P , Svennevig JL. Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass . Artif Organs 1991; 15: 90-95 .

16.

Mollnes TE , Videm V , Christiansen D , Bergseth G , Riesenfeld J , Hovig T. Platelet compatibility of an artificial surface modified with functionally active heparin . Thromb Haemost 1999; 82: 1132-1136 .

17.

Wendel HP , Ziemer G. Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation . Eur J Cardiothorac Surg 1999; 16: 342-350 .

18.

Hsu LC. Biocompatibility in cardiopulmonary bypass . J Cardiothorac Vasc Anesth 1997; 11: 376-382 .

19.

Hsu LC. Heparin-coated cardiopulmonary bypass circuits: current status . Perfusion 2001; 16: 417-428 .

20.

Larm O , Larsson R , Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue . Biomater Med Devices Artif Organs 1983; 11: 161-173 .

21.

Ovrum E , Mollnes TE , Fosse E , et al. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits . J Thorac Cardiovasc Surg 1995; 110: 1623-1632 .

22.

Ovrum E , Tangen G , Oystese R , Ringdal MA , Istad R. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations . J Thorac Cardiovasc Surg 2001; 121: 324-330 .

23.

Baksaas ST , Videm V , Fosse E , et al. In vitro evaluation of new surface coatings for extracorporeal circulation . Perfusion 1999; 14: 11-19 .

24.

Wimmer-Greinecker G , Matheis G , Martens S , Oremek G , Abdel-Rahman U , Moritz A. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences . Eur J Cardiothorac Surg 1999; 16: 211-217 .

25.

Lee JH , Kopeckova P , Kopecek J , Andrade JD. Surface properties of copolymers of alkyl methacrylates with methoxy (polyethylene oxide) methacrylates and their application as protein-resistant coatings . Biomaterials 1990; 11: 455-464 .

26.

Han DK , Jeong SY , Kim YH. Evaluation of blood compatibility of PEO grafted and heparin immobilized polyurethanes . J Biomed Mater Res 1989; 23: 211-228 .

27.

Ito Y , Iguchi Y , Kashiwagi T , Imanishi Y. Synthesis and nonthrombogenicity of polyetherurethaneurea film grafted with poly(sodium vinyl sulfonate) . J Biomed Mater Res 1991; 25: 1347-1361 .

28.

Silver JH , Hart AP , Williams EC , et al. Anticoagulant effects of sulphonated polyurethanes . Biomaterials 1992; 13: 339-344 .

29.

Keldenich S , Kopp R , Kirschfink M , et al. Application of a new dynamic flow model for investigating the biocompatibility of modified surfaces . ASAIO J 2000; 46: 134-141 .

30.

Cazzaniga A , Ranucci M , Isgro G , et al. Trillium biopassive surface: a new biocompatible treatment for extracorporeal circulation circuits . Int J Artif Organs 2000; 23: 319-324 .

31.

Baksaas ST , Videm V , Pedersen T , et al. Comparison of three oxygenator-coated and one total-circuit-coated extracorporeal devices . Perfusion 1999; 14: 119-127 .

32.

Tevaearai HT , Mueller XM , Seigneul I , et al. Trillium coating of cardiopulmonary bypass circuits improves biocompatibility . Int J Artif Organs 1999; 22: 629-634 .

33.

Palanzo DA , Zarro DL , Montesano RM , et al. Effect of Trillium Biopassive Surface coating of the oxygenator on platelet count drop during cardiopulmonary bypass . Perfusion 1999; 14: 473-479 .

34.

Niimi Y , Ishiguro Y , Nakata Y , Goto T , Morita S , Yamane S. Platelet adhesion to heparin coated oxygenator fibers under in vitro static conditions: impact of temperature . ASAIO J 2001; 47: 361-364 .

35.

Ereth MH , Nuttall GA , Clarke SH , et al. Biocompatibility of trillium biopassive surface-coated oxygenator versus uncoated oxygenator during cardiopulmonary bypass . J Cardiothorac Vasc Anesth 2001; 15: 545-550 .

36.

Stammers AH , Christensen KA , Lynch J , Zavadil DP , Deptula JJ , Sydzyik RT. Quantitative evaluation of heparin-coated versus non-heparin-coated bypass circuits during cardiopulmonary bypass . J Extra Corpor Technol 1999; 31: 135-141 .

Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery

Abstract

Get full access to this article

References